Metabolic Deregulations in Patients with Polycystic Ovary Syndrome

Abstract

Polycystic ovary syndrome (PCOS) contributes to endocrine and metabolic complications for women worldwide. The aim of this study was to establish the usefulness of new anthropometric indices and atherogenic indices in the evaluation of metabolic disorders, in particular, glucose and insulin abnormalities in the profiles of women with polycystic ovary syndrome (PCOS). In the study, a total of 49 women with PCOS aged between 18 and 39 years were recruited. All patients were tested for fasting glucose and insulin, lipid parameters, oral-glucose administration, and biochemical parameters. All of them underwent anthropometric measurements, such as BMI (body mass index), WHR (waist-to-hip ratio), WHtR (waist-to-height ratio), BAI (body adiposity index), VAI (visceral adiposity index), LAP (lipid accumulation product), BRI (body roundness index), ABSI (A body shape index), AIP (atherogenic risk of plasma), AC (atherogenic coefficient), Castelli risk index-I, Castelli risk index-II and (LCI) lipoprotein combine index, TG/HDL-C ratio, METS-IR (The metabolic score of insulin resistance), triglyceride glucose index (TyG index), triglyceride glucose-body mass index (TyG-BMI index) and triglyceride glucose-waist circumference index (TyG-WC index) were calculated. The analyzed anthropometric measurements/indices and atherogenic indices demonstrated significant correlations in PCOS women. T A strong relationship was found between fasting glucose, fasting insulin, glucose after 60 min, HOMA-IR index in the patients with PCOS. There was no significant relationship between HbA1c and other analyzed parameters and indices. Most of the analyzed anthropometric and atherogenic indices may be useful tools in evaluating metabolic disorders, and, in particular, glucose and insulin abnormalities in PCOS women.

The Role of Different Methods in Defining Cardiometabolic Risk and Metabolic Syndrome in Women with Polycystic Ovary Syndrome

“…Among the anthropometric indices, the VAI and LAP index were the highest, while ABSI and WHR were the lowest predictors [29]. Although Krauker and Krauker (2014) reported that ABSI, which they developed as an abdominal adiposity marker using WC and the BMI, is a more reliable marker for premature mortality than other anthropometric measurements [95], ABSI seems to have a low effect on explaining metabolic risk factors, including in this study [3,29,84,94].…”

“…In the study by Jabczyk et al (2023), glycemic parameters and various indices, including the LAP index, VAI, BRI, and ABSI, were evaluated in PCOS patients [94]. ABSI was reported to have the lowest significance, while the BMI and WC were significantly correlated with glycemic parameters; the LAP index and VAI were found to have a significant relationship with metabolic disorders [94]. In this study, according to the multivariate logistic regression model, the BRI was one of the strongest independent predictors of MetS.…”

“…It is thought that the discriminatory power is high in the studies due to the use of TGs and HDL-C parameters, which are among the MetS criteria, in the LAP index and VAI formulations. In the study by Jabczyk et al (2023), glycemic parameters and various indices, including the LAP index, VAI, BRI, and ABSI, were evaluated in PCOS patients [94]. ABSI was reported to have the lowest significance, while the BMI and WC were significantly correlated with glycemic parameters; the LAP index and VAI were found to have a significant relationship with metabolic disorders [94].…”

Association Between Insulin Resistance Indices and Liver Function Parameters Among Women With Polycystic Ovary Syndrome

“…This is because liver is a core organ in which lipid and glucose metabolism regulation occur [ 52 ]. It is also well‐believed that IR is a key factor in the pathophysiology of liver disease, and lipid markers such as the TG/HDL‐C ratio and TyG index are useful tools for evaluating metabolic dysregulations like insulin levels and IR in women with PCOS [ 53 , 54 , 55 , 56 , 57 ].…”

The Role of Lipid Accumulation Product (LAP) as a Metabolic Indicator in Polycystic Ovary Syndrome (PCOS)

“…24 Additionally, Jabczyk et al showed a significant association of LAP with metabolic disorders (both glucose/insulin levels and lipid profiles) in PCOS women (p = 0.000). 25 However, despite the body of evidence supporting the utilization of LAP in women diagnosed with PCOS, there remain certain gaps in our comprehension and inconsistencies within the existing literature that require further attention. One area that demands additional investigation is determining the most suitable cutoff values for LAP that accurately predict metabolic risk and IR in women living with PCOS.…”